For RA patients previously treated with HCQ/SSZ/LEF who have low disease activity, what is the recommended management step?

• A. Continue the same regimen
• B. Switch to MTX
• C. Switch to alternative HCQ/SSZ/LEF
• D. Add a bDMARD

Answer: (C)

When rheumatoid arthritis is well controlled on conventional synthetic DMARDs, the goal is to maintain that control while minimizing long-term toxicity and costs. Rotating the regimen to an alternative combination of HCQ, sulfasalazine, and leflunomide can preserve efficacy but reduce the risk of adverse effects tied to a single drug and avoid jumping to biologics too soon. If disease activity is already low, there’s no need to escalate to a biologic; continuing exactly the same mix without considering tolerability or safety isn’t ideal, and simply sticking with the same trio may miss an opportunity to optimize safety. Switching to an alternative HCQ/SSZ/LEF combination aims to keep disease control stable with a potentially better safety/tolerability profile.